Weleader Biomedical CoROCO:7713 -1.54%47 EV-to-FCF is 37.34 as of Jul. 02, 2026, which is 7% below its 10-year median of 40.35. GuruFocus rates ROCO:7713 with a GF Score™ of 47/100. The stock has 5 warning signs investors should review. Among 418 Medical Devices & Instruments companies, Weleader Biomedical Co ranks worse than 68.42% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Weleader Biomedical Co's Enterprise Value is NT$3,717 Mil.
Weleader Biomedical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$100 Mil. Therefore, Weleader Biomedical Co's EV-to-FCF for today is 37.34.
The historical rank and industry rank for Weleader Biomedical Co's EV-to-FCF or its related term are showing as below:
ROCO:7713'
s EV-to-FCF Range Over the Past 10 Years
Min: -2541.92 Med: 40.35 Max: 182.61
Current: 37.75
During the past 6 years, the highest EV-to-FCF of Weleader Biomedical Co was 182.61. The lowest was -2541.92. And the median was 40.35.
ROCO:7713's EV-to-FCF is ranked worse than 68.42% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 22.58
vs ROCO:7713: 37.75
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Weleader Biomedical Co (ROCO:7713) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Weleader Biomedical Co's PE Ratio (TTM) for today is calculated as:
Weleader Biomedical Co's share price for today is NT$70.10.
Weleader Biomedical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$4.510.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Weleader Biomedical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Weleader Biomedical Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Weleader Biomedical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Weleader Biomedical Co's EV-to-FCF falls into.
Weleader Biomedical Co's current Enterprise Value is NT$3,717 Mil.
Weleader Biomedical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$100 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Weleader Biomedical Co (ROCO:7713) has a EV-to-FCF of 37.34 as of Jul. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Weleader Biomedical Co and its competitors. This is near median its historical median of 40.35. According to the industry distribution chart, Weleader Biomedical Co ranks #286 out of 418 companies in the Medical Devices & Instruments industry, placing it in the top 68.4%.
Is Weleader Biomedical Co's EV-to-FCF too high?
Weleader Biomedical Co's current EV-to-FCF of 37.34 is near median its 10-year median of 40.35. The Medical Devices & Instruments industry median EV-to-FCF is 22.58. Weleader Biomedical Co's value of 37.34 is 65.4% above this industry median. Based on the distribution chart, Weleader Biomedical Co ranks #286 out of 418 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Weleader Biomedical Co has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Weleader Biomedical Co ranks #286 out of 418 companies for EV-to-FCF. This places Weleader Biomedical Co in the lower half of its industry. The industry median EV-to-FCF is 22.58. Weleader Biomedical Co's value of 37.34 is 65.4% above this benchmark. While the company's 10-year median is 40.35 vs. the industry median of 22.58, Weleader Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.58, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Weleader Biomedical Co's current EV-to-FCF of 37.34 is 65.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Weleader Biomedical Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Weleader Biomedical Co's current EV-to-FCF is 37.34, which is near median its own 10-year median of 40.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current EV-to-FCF of 37.34. The current EV-to-FCF is 37.34, which is near median its 10-year median of 40.35 and 65.4% above the Medical Devices & Instruments industry median of 22.58. Weleader Biomedical Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current EV-to-FCF is 37.34 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
47GF Score
Get the complete analysis for ROCO:7713
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7713 has been successfully added to your 
